[quote]Apnimed reported that its experimental drug achieved a 46.8% reduction in sleep apnea severity after 26 weeks in a Phase 3 trial, compared to just 6.8% improvement with placebo. The once-daily pill combines aroxybutynin and atomoxetine to target the underlying neuromuscular causes of airway collapse during sleep. Separately, Incannex announced that its candidate reduced breathing interruptions by up to 83% in Phase 2 trials.
[quote]Both medications represent a departure from traditional sleep apnea treatments. Current options include CPAP machines, which deliver pressurized air through a mask, oral appliances, and surgical procedures. However, less than 50% of patients consistently use CPAP therapy due to discomfort.